Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01

Yunda Huang (), Lily Zhang, Shelly Karuna, Philip Andrew, Michal Juraska, Joshua A. Weiner, Heather Angier, Evgenii Morgan, Yasmin Azzam, Edith Swann, Srilatha Edupuganti, Nyaradzo M. Mgodi, Margaret E. Ackerman, Deborah Donnell, Lucio Gama, Peter L. Anderson, Richard A. Koup, John Hural, Myron S. Cohen, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert and Maria P. Lemos
Additional contact information
Yunda Huang: Fred Hutchinson Cancer Center
Lily Zhang: Fred Hutchinson Cancer Center
Shelly Karuna: Fred Hutchinson Cancer Center
Philip Andrew: Family Health International
Michal Juraska: Fred Hutchinson Cancer Center
Joshua A. Weiner: Dartmouth College
Heather Angier: Fred Hutchinson Cancer Center
Evgenii Morgan: Fred Hutchinson Cancer Center
Yasmin Azzam: Fred Hutchinson Cancer Center
Edith Swann: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
Srilatha Edupuganti: Emory University School of Medicine
Nyaradzo M. Mgodi: University of Zimbabwe Clinical Trials Research Centre
Margaret E. Ackerman: Dartmouth College
Deborah Donnell: Fred Hutchinson Cancer Center
Lucio Gama: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Peter L. Anderson: University of Colorado-AMC
Richard A. Koup: National Institute of Allergy and Infectious Diseases, National Institutes of Health
John Hural: Fred Hutchinson Cancer Center
Myron S. Cohen: University of North Carolina at Chapel Hill
Lawrence Corey: Fred Hutchinson Cancer Center
M. Juliana McElrath: Fred Hutchinson Cancer Center
Peter B. Gilbert: Fred Hutchinson Cancer Center
Maria P. Lemos: Fred Hutchinson Cancer Center

Nature Communications, 2023, vol. 14, issue 1, 1-19

Abstract: Abstract Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials. In 48 US participants (men and transgender persons who have sex with men) who received the HIV-1 mAb VRC01 and remained HIV-free in an antibody-mediated-prevention trial (ClinicalTrials.gov #NCT02716675), we conduct a post-hoc analysis and find that VRC01 clearance is 0.08 L/day faster (p = 0.005), and dose-normalized area-under-the-curve of VRC01 serum concentration over-time is 0.29 day/mL lower (p

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-43399-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-43399-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-43399-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().